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Summary
 
Chemotherapeutic drugs cause DNA damage and kill cancer cells mainly by apoptosis. p53
mediates apoptosis after DNA damage. To explore the pathway of p53-dependent cell death,
we investigated if p53-dependent apoptosis after DNA damage is mediated by the CD95
(APO-1/Fas) receptor/ligand system. We investigated hepatoma, gastric cancer, colon cancer,
and breast cancer cell lines upon treatment with different anticancer agents known to act via
p53 accumulation. Cisplatin, mitomycin, methotrexate, mitoxantrone, doxorubicin, and bleo-
mycin at concentrations present in the sera of patients during therapy led to an upregulation of
both CD95 receptor and CD95 ligand. Induction of the CD95 ligand occurred in p53 wild-
type (wt), p53 mutant (mt), and p53 deficient (p53
 
2
 
/
 
2
 
) cell lines and at wt and mt conforma-
tion of temperature-sensitive p53 mutants. In contrast, upregulation of the CD95 receptor was
observed only in cells with wt p53, not in cells with mt or without any p53. Restitution of in-
ducible wt p53 function restored the ability of p53
 
2
 
/
 
2
 
 Hep3B cells to upregulate the CD95 re-
ceptor in response to anticancer drugs. This rendered the cells sensitive to CD95-mediated apop-
tosis. In an attempt to understand how CD95 expression is regulated by p53, we identified a
p53-responsive element within the first intron of the CD95 gene, as well as three putative ele-
ments within the promoter. The intronic element conferred transcriptional activation by p53
and cooperated with p53-responsive elements in the promoter of the CD95 gene. wt p53
bound to and transactivated the CD95 gene, whereas mt p53 failed to induce apoptosis via ac-
tivation of the CD95 gene. These observations provide a mechanistic explanation for the abil-
ity of p53 to contribute to tumor progression and to resistance of cancer cells to chemotherapy.
Key words: apoptosis • CD95 (APO-1/Fas) • p53 • cancer therapy • drug resistance
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esistance of tumor cells to chemotherapy remains an
obstacle to the successful treatment of human cancer.
Combination chemotherapy has had a significant impact on
survival from malignancies such as Hodgkin’s disease, tes-
ticular cancer, and childhood acute leukemias. However,
the majority of cancers are either initially resistant to che-
motherapy, e.g., colon, renal, and hepatocellular cancer, or
are initially chemosensitive but acquire resistance to a broad
spectrum of drugs during treatment, such as lymphoma or
breast cancer. One explanation for multidrug resistance in
some tumors is the increased activity of the p-glycoprotein,
a product of the mdr1 gene and an energy-dependent mul-
tidrug transporter that acts to decrease the cellular efflux of
many drugs. However, amplification of mdr1 accounts for
only a small percentage of cancers with a multidrug resis-
tance phenotype. Drugs found to be efficacious in the
treatment of cancer include diverse chemical compounds
such as antimetabolites (e.g., methotrexate and fluorou-
racil), DNA-damaging agents (e.g., cyclophosphamide,
cisplatin, and doxorubicin), mitotic inhibitors (e.g., vin-
cristine), nucleotide analogues (e.g., 6-mercaptopurine),
inhibitors of topoisomerases involved in DNA repair (e.g.,
etoposide), inhibitors of DNA polymerase (e.g., bleomy-
cin), or intercalating agents like mitoxantrone. For years it
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has been known that these diverse drugs can induce apop-
tosis (1, 2). However, the mechanism of apoptosis induced
by the drugs was not known. Recent evidence (3–6) sug-
gests that genes that regulate apoptotic cell death may play
an important role in determining the sensitivity of tumor
cells to chemotherapy.
Friesen et al. (3) and Müller et al. (6) have shown that
death induced in tumor cells by anticancer treatment is an
active program of the cell which involves the CD95 system,
one of the key regulatory systems of apoptosis. Treatment of
leukemic and hepatocellular carcinoma cell lines, respec-
tively, in vitro with chemotherapeutic agents causes upreg-
ulation of the CD95 ligand (CD95L), activating both an
autocrine suicide and a fratricide death system. CD95L is
expressed in a membrane form or is released by the tumor
cells exposed to the drug. Binding of CD95L to the CD95
receptor then initiates the apoptotic signal in chemosensi-
tive cells. Furthermore, we have shown for hepatoma cells
that in addition to the expression of CD95L, cells treated
with anticancer drugs upregulate CD95 receptor expres-
sion (6).
The presence of functional wild-type (wt)
 
1
 
 p53 is closely
coupled with efficient induction of CD95-mediated apop-
tosis in many (6–8) but not all (9, 10) cell types. Upregula-
tion of the CD95 receptor—after anticancer therapy—in
hepatocellular carcinomas was preceded and directed by
upregulated p53 and, thus, only occurred in hepatoma cell
lines that express wt p53 (6). p53 has multiple functions
(11–13), including cell cycle control in response to DNA
damage (14, 15), induction of apoptosis (16–19), and DNA
repair (20–22). Anticancer therapy causes damage of the
DNA in the treated cells. p53 modulates cellular responses
to DNA damage in mammals, affecting cell cycle progres-
sion and/or programmed cell death. Although the cyclin-
dependent kinase inhibitor CDKN1A, also known as p21,
appears to be the major effector of p53-mediated G1 cell
cycle arrest after DNA damage (23–26), the mechanism by
which p53 signals influence the apoptotic machinery after
DNA damage remains unclear. p53 also acts as a sequence-
specific DNA binding protein which activates the tran-
scription of target genes. The proapoptotic protein BAX
appears to be transcriptionally induced by p53 after DNA
damage in certain cell types (27). However, BAX appears
to contribute only in part to p53-mediated cell death (28).
Based on our observation that the CD95 receptor was
only upregulated in cancer cells carrying wt p53 after DNA
damage and on the fact that forced overexpression of wt
p53 can stimulate CD95 gene transcription (29), we inves-
tigated if the CD95 system is activated and/or regulated by
p53 in a variety of human solid cancer cell lines. These cell
lines are representative of the “major killers” among human
tumors, in which p53 mutations are known to play an im-
portant role. Thus, colon, stomach, hepatoma, and breast
cancer cell lines with different p53 status were evaluated.
We applied anticancer drugs with different mechanisms of
action but concentrated on drugs that use the p53 pathway.
Our data demonstrate that drug-induced p53 upregulation
is involved in CD95 gene induction and apoptosis. Induc-
tion of CD95 gene transcription by p53 is mediated
through a strong p53-responsive element located within
the first intron of the gene. This element cooperates with
sequences in the CD95 promoter to achieve maximal
transactivation by wt p53.
 
Materials and Methods
 
Cell Lines.
 
The following cell lines were used: (
 
a
 
) HepG2
cells derived from a human hepatoblastoma (30) only expressing
small amounts of wt p53 (31; our unpublished sequence data); (
 
b
 
)
Huh7 cells derived from a hepatocellular carcinoma (32) and
shown to express p53 with increased half-life as a result of a point
mutation at codon 220 (33); (
 
c
 
) Hep3B cells (30) deficient of p53
(31); (
 
d
 
) Hs746T gastric cancer cells expressing wt p53; (
 
e
 
) HT29
colon cancer cells with mt p53 (34, 35); (
 
f
 
) AGS colon cancer
cells with wt p53; (
 
g
 
) MCF7 breast cancer cells expressing wt p53
(36, 37); and (
 
h
 
) H1299 human lung adenocarcinoma cells defi-
cient of p53 (38). HepG2, Huh7, and Hs746T cells were main-
tained in DME (GIBCO BRL, Eggenstein, Germany) containing
10% FCS, 5 mM 
 
l
 
-glutamine, and 100 
 
m
 
g/ml penicillin (GIBCO
BRL). Hep3B cells were grown in MEM (Laboratoires Eurobio,
Raunheim, Germany). HT29, MCF7, and H1299 cells were cul-
tured in RPMI 1640 medium (GIBCO BRL) supplemented with
10% heat-inactivated FCS (GIBCO BRL), 10 mM Hepes, pH
7.3 (GIBCO BRL), 100 U/ml streptomycin (GIBCO BRL), and
2 mM 
 
l
 
-glutamine (GIBCO BRL). AGS cells were propagated
in Ham’s F-12 medium (GIBCO BRL) supplemented with 10%
heat-inactivated FCS, 10 mM Hepes, pH 7.3, 100 U/ml strepto-
mycin, and 2 mM 
 
l
 
-glutamine.
 
Transfections.
 
Before transfection, H1299 and Hep3B cells
were seeded at 0.6 
 
3 
 
10
 
6
 
 cells/6-cm dish. The medium was
changed to DME supplemented with 10% FCS, and cells were
transfected by the calcium phosphate method with the precipitate
left on cells for 16 h. Next, cells were glycerol shocked for 1 min
and plated in RPMI medium supplemented with 10% FCS. Cells
were harvested 24 h later and assayed for luciferase activity as de-
scribed previously (39).
For preparation of cell extracts for immunoselection assays,
H1299 cells were plated at a density of 1.2 
 
3 
 
10
 
6
 
/10-cm dish and
transfected as above with 5 
 
m
 
g pCMVp53wt (40) DNA.
 
Generation of Stable Hep3B-derived Clones.
 
Stable Hep3B-
derived clones were generated in which wt p53 activity can be
deliberately induced. Hep3B cells are particularly appropriate for
our studies because they lack p53 (30, 31, 41). Stable Hep3B
clones were generated expressing either puromycin resistance
alone (control cell line: BT-2E) or in conjunction with either the
temperature-sensitive mutant p53val135 (42) or a p53 (modi-
fied)–estrogen receptor chimera in which p53 activity is induced
posttranslationally by addition of the specific ligand 4-OH
tamoxifen (cell line: BT-4P) (43). These cell lines have been de-
scribed (41).
A third type of stably transfected Hep3B clones was established
expressing the temperature-sensitive mutant p53ala143 (44).
Transfection was performed by calcium phosphate precipitation
with p53ala143. 2 d later G418 (Sigma Chemical Co., Munich,
 
1
 
Abbreviations used in this paper:
 
 IGF-IR, insulin-like growth factor I re-
ceptor; MANOVA, multivariate analysis of variance; mt, mutated; wt,
wild-type. 
2035
 
Müller et al.
Germany) was added, and cells were maintained under G418 se-
lection. After 
 
z
 
14–21 d, G418-resistant colonies were recovered
and expanded.
4-OH tamoxifen was purchased from Sigma Chemical Co.
and stored at –20
 
8
 
C as a 1 mM stock solution in DMSO. A 100
 
m
 
M working stock in DMSO was used for direct addition to cul-
tured cells. Puromycin was purchased from Sigma Chemical Co.
and stored at –20
 
8
 
C as a sterile solution of 1 mg/ml in water.
 
Treatment with Anticancer Agents.
 
The different cell lines were
treated with bleomycin (Heinrich Mack Nachf., Illertissen, Ger-
many) at a dose range of 60 ng/ml to 6 mg/ml, or with doxoru-
bicin (Rhône-Poulenc Rorer GmbH, Köln, Germany) at a dose
range of 0.4 ng/ml to 4 
 
m
 
g/ml for 3–72 h. Additionally, cisplatin
at a dose range of 0.1 ng/ml to 0.1 mg/ml or methotrexate at a
dose range of 0.1 ng/ml to 1 mg/ml was applied. The concentra-
tions relevant for therapy are 1.5–3 
 
m
 
g/ml for bleomycin (45), 0.4–
1.6 
 
m
 
g/ml for cisplatin (46, 47), 7–12 
 
m
 
g/ml for methotrexate (48),
and 0.001–0.02 
 
m
 
g/ml for doxorubicin (49) in patients’ sera.
 
Treatment with IgG3 Anti–APO-1.
 
The CD95 receptor was
stimulated with the mAb IgG3 anti–APO-1 at concentrations of
100 ng/ml as described (50–52).
 
Detection of Apoptosis.
 
Apoptosis was assessed by FACS
 
Ò
 
 anal-
ysis carried out in a FACScan
 
Ò
 
 flow cytometer (Becton Dickin-
son GmbH, Heidelberg, Germany) using CellQuest software.
Quantification of DNA fragmentation was performed by
FACS
 
Ò
 
 analysis of propidium iodide–stained nuclei as described
previously (53). Hepatocytes floating in the culture medium were
collected by centrifugation at 200 
 
g
 
. Adherent hepatocytes were
harvested by incubation with 1% trypsin for 1 min. The cells
were washed with PBS, suspended in hypotonic lysis buffer (0.1%
sodium citrate; Merck, Darmstadt, Germany), 0.1% Triton X
(Serva Feinbiochemica, Heidelberg, Germany), and 50 ng/ml
propidium iodide (Sigma Chemical Co.) and incubated at 4
 
8
 
C for
6 h. Cells were then analyzed for DNA content by flow cytometry.
Early apoptotic changes were identified by using Annexin-V-
Fluos (Boehringer Mannheim GmbH, Mannheim, Germany),
which binds to phosphatidylserine exposed on the outer leaflet of
apoptotic cell membranes. Propidium iodide was used for the dis-
crimination of necrotic cells from the annexin V positively
stained cell cluster. Cells were trypsinized, washed with PBS,
centrifuged at 200 
 
g
 
 for 5 min, and resuspended in 100 
 
m
 
l An-
nexin-V-Fluos labeling solution containing 20 
 
m
 
l Annexin-V-
Fluos labeling reagent in 1,000 
 
m
 
l Hepes buffer (10 mM Hepes/
NaOH, pH 7.4, 140 mM NaCl, 5 mM CaCl
 
2
 
) and 20 
 
m
 
l propid-
ium iodide. Cells were incubated for 10–15 min and analyzed on
a flow cytometer using CellQuest software. A 488-nm excitation
and a filter 
 
.
 
560 nm for propidium iodide detection were used.
 
Detection of the CD95 (APO-1/Fas) Receptor.
 
Cell surface ex-
pression of the CD95 receptor was assessed by FACScan
 
Ò
 
. Anti–
APO-1 (IgG3, 
 
k
 
) was used as purified biotinylated antibody.
Quantum Red streptavidin (Sigma Chemical Co.) was used as
secondary reagent for indirect immunofluorescence. Hepatoma
cells were incubated in 50 
 
m
 
l culture medium with biotinylated
anti–APO-1. After 30 min incubation, cells were washed twice,
incubated for 30 min with Quantum Red streptavidin, washed
twice again, and assayed. Upon data acquisition a gate was set on
intact cells by forward/side scatter analysis, and 10
 
4
 
 viable cells
were analyzed. Percent enhanced CD95 expression was calcu-
lated according to the formula (% CD95
 
1
 
 treated cells 
 
2 
 
%
Quantum Red
 
1
 
 treated cells) 
 
2 
 
(% CD95
 
1
 
 control cells 
 
2 
 
%
Quantum Red
 
1
 
 control cells).
 
Detection of CD95L mRNA Expression by PCR.
 
Total cellular
RNA was prepared from 3 
 
3 
 
10
 
6
 
 cells treated with different anti-
cancer drugs, using the RNeasy Kit (QIAGEN GmbH, Hilden,
Germany) according to the manufacturer’s instructions. Expres-
sion of 
 
b
 
-actin (MWG Biotech GmbH, Ebersberg, Germany)
was used as an internal standard for RNA integrity and equal gel
loading. 1 
 
m
 
g of total cellular RNA was retrotranscribed after
heat denaturation (3 min, 60
 
8
 
C) and annealing with oligo (dT)
primers (16-mer; Perkin Elmer, Weiterstadt, Germany) in the
presence of 75 U MnLV RT (Perkin Elmer), 67 
 
m
 
M MgCl
 
2
 
, and
63 
 
m
 
M of each dNTP in 20 
 
m
 
l for 45 min at 42
 
8
 
C. Reactions
were stopped by heat inactivation for 5 min at 90
 
8
 
C. Aliquots of
10 
 
m
 
l of the cDNA were then amplified in a DNA thermocycler
(Stratagene Inc., Heidelberg, Germany) with 2.5 U of Ampli Taq
DNA polymerase AS (Perkin Elmer), 10 pM of both upstream
and downstream APO-1L primers, and 2.5 
 
m
 
M of both upstream
and downstream human 
 
b
 
-actin primers in a 50 
 
m
 
l vol. Each
PCR cycle consisted of a denaturation step (94
 
8
 
C, 1 min), an an-
nealing step (56
 
8
 
C, 1 min), and an elongation step (72
 
8
 
C, 1 min).
The primers used for amplification of the CD95L have been de-
scribed (54). The PCR products were analyzed on a 1.4% TBE
(Tris-borate-EDTA) agarose gel.
 
Cytotoxicity Assay: MTT Assay.
 
The MTT assay is a colori-
metric assay based on the ability of the viable cells to reduce a sol-
uble yellow tetrazolium salt (MTT) to blue formazan crystals. A
100-
 
m
 
l suspension of 7 
 
3 
 
10
 
3
 
 cells was added to each well of 96-
well plates 24 h before the assay. Various concentrations of the
different anticancer drugs, IgG3 anti–APO-1, and F(ab
 
9
 
)
 
2 
 
anti–
APO-1 fragments were added to the cells. After 3–72 h, 5 mg/ml
of MTT dye was added and the plates were incubated for 12 h.
OD was determined by eluting the dye with isopropanol/formic
acid, and absorbance was measured at 540 nm.
Results are shown as the mean of data from six independent
wells 
 
6
 
 SD. To rule out that drug-treated cells may simply arrest
growth, making it difficult to determine what percentage of the
reduced MTT is due to apoptosis, all cytotoxicity assays were
verified by FACS
 
Ò
 
 analysis using the method of Nicoletti et al.
(53) to assess the subdiploid DNA content and specific apoptosis.
 
Immunoselection of p53-binding DNA Fragments.
 
DNA of cosmid
cAPO-1 (55) was digested to completion with Sau3A1. The mix-
ture of small DNA fragments was ligated into the BamHI site of
pBlueScript II KS
 
1
 
, and the ligation products were transformed
into 
 
Escherichia coli
 
. Transformants were selected in liquid culture
containing ampicillin, and DNA was prepared for the drug-resis-
tant culture. The DNA was taken through three consecutive
rounds of p53 immunoselection. The procedure was essentially as
described in Zauberman et al. (56), except that the extracts used
for selection were prepared from H1299 cells transiently trans-
fected with a p53 expression plasmid (pCMVp53wt) and har-
vested 40 h after transfection. At the end of the third selection cy-
cle, digestion of the enriched plasmid DNA revealed only a single
insert band of 0.7 kb. Single colonies were obtained from the en-
riched plasmid population, the corresponding plasmids were ex-
tracted, and each was confirmed for the presence of the expected
0.7-kb insert. The insert was then subjected to DNA sequencing,
and used for construction of luciferase-based reporter plasmids.
 
Plasmids.
 
Plasmid pCMVp53wt, encoding mouse wt p53, has
been described previously (40). Plasmid CD95(Ps)-luc was con-
structed by ligating a 1.71-kb HindIII-SacII fragment of cosmid
cAPO-1 (55), containing the 1.43-kb 3
 
9
 
 end of the human CD95
gene promoter and the 5
 
9
 
 end of exon 1 (0.28 kb) (57), into
pGL3-Basic (Promega Corp., Madison, WI) or into pTATA-Luc
(a gift of T. Wirth, Institut für Medizinische Strahlen-und Zell-
forschung, Würzburg, Germany). Plasmid CD95(P)-luc, contain-
ing an extended 5
 
9 version of the CD95 promoter (1.9 kb) and2036 p53 and CD95 in Drug-induced Apoptosis
the 59 end of exon 1 (0.28 kb) (57), was constructed by cloning a
450-bp PCR fragment of the 59 part of the CD95 promoter (58)
in the HindIII site of CD95(Ps)-luc. Orientation of the PCR
fragment and sequence was checked by sequencing. Plasmid
CD95(I1SV)-luc was constructed by ligating a 0.7-kb CD95
gene fragment of intron 1 (excised from the pBlueScript vector
with SacI1SalI) between the SacI and XhoI sites of pGL3-Pro-
moter (Promega Corp.); this places the intronic CD95 fragment
upstream of a minimal SV40 promoter, followed by the luciferase
reporter. CD95(Ps1I)-luc and CD95(Ps1Is)-luc were generated
by inserting the above 0.7-kb fragment or a HindIII-cleaved
0.6-kb subfragment thereof, respectively, downstream of the
CD95 promoter in plasmid CD95(Ps)-luc. Cyclin G luciferase
contains the cyclin G gene promoter in front of a luciferase
reporter (59).
Statistical Analysis. To examine whether synergy (60, 61) be-
tween APO-1 stimulation and concurrent chemotherapeutic
treatment is observed, a balanced two-way ANOVA (model with
fixed effects) was performed. In addition, we applied MANOVA
(multivariate analysis of variance) to test for statistical significance.
Statistical analysis was carried out with SAS software (SAS Insti-
tute, Inc., Cary, NC).
Results
Induction of Apoptosis by Anticancer Drugs
The anticancer drugs 5-fluorouracil, methotrexate, mito-
mycin, cisplatin, mitoxantrone, doxorubicin, etoposide, cy-
clophosphamide, and bleomycin have been shown to trigger
nuclear accumulation of the tumor suppressor protein p53
(6, 62). To analyze whether these drugs use the CD95 sys-
tem to exert their cytotoxic effects, we first investigated if
they induce apoptosis. We found that all of the above drugs
irrespective of their intracellular target cause death of sensi-
tive target cells by inducing apoptosis (Table 1). Having
established that the accumulation of p53 by DNA damage
upon treatment with anticancer drugs resulted in induction
of apoptosis, we investigated if the CD95 receptor/ligand
system is involved in p53-mediated apoptosis.
Induction of the CD95 Receptor by Anticancer Drugs
Treatment with 5-fluorouracil, methotrexate, mitomy-
cin, cisplatin, mitoxantrone, doxorubicin, etoposide, cyclo-
Table 1. Induction of CD95 and Apoptosis by Anticancer Drugs in Cell Lines with wt p53
Drug* Mechanism of action
Concentration
tested for CD95
receptor induction‡
CD95 receptor
induction, increase
above controls§
Increased responsiveness towards
induction of apoptosis by CD95
receptor stimulationi
mg/ml % %
Fluorouracil Pyrimidine antagonist 2.5–2,500 5–62¶ 46–55
Methotrexate Folic acid antagonist 0.25–2,500 8–65¶ 28–70
Mitomycin Alkylation 0.01–100 3–56¶ 0–53
Cisplatin Alkylation 0.1–100 0–60** 0–64
Cyclophosphamide Alkylation 0.001–100 28–40‡‡ 39–45
Mitoxantrone Intercalation 0.0001–1 8–52‡‡ 43–51
Doxorubicin Intercalation 0.002–2 1§§ 18–43
Etoposide Inhibits topoisomerase II 0.001–1 22–55‡‡ 45–62
Bleomycin¶¶ Inhibits DNA polymerase 0.3–3,000 15–78ii 27–73
*Anticancer drugs with different mechanisms of action were analyzed for their ability to induce the CD95 receptor. Different solid human cancer
cell lines (HepG2, Hs746T, AGS, MCF7, Huh7, and HT29) were treated with the specific anticancer drug for 48 h.
‡A wide range of drug concentrations were tested. Clinically relevant concentrations of the chemotherapeutic drugs are marked with an asterisk in
Fig. 2.
§Treatment with 5-fluorouracil, methotrexate, mitomycin, cisplatin, mitoxantrone, doxorubicin, etoposide, cyclophosphamide, and bleomycin led to
upregulation of the CD95 receptor in HepG2 cells (wt p53), in AGS cells (wt p53), in Hs746T cells (wt p53), and in MCF7 cells (wt p53). No in-
duction or only weak induction of the CD95 receptor was observed in cell lines with mutant p53 (Huh7 and HT29) and in cell lines lacking p53
(Hep3B). Cell surface expression of the CD95 receptor was assessed by FACScanÒ. Percent CD95 induction was calculated as (% CD951 treated
cells 2 % Quantum Red1 treated cells) 2 (% CD951 control cells 2 % Quantum Red1 control cells).
iThe upregulation of the CD95 receptor after cytostatic treatment is functional. It provides the cell with an increased responsiveness towards CD95-
mediated apoptosis. Hepatoma cells with different p53 mutational status were treated with diverse anticancer drugs alone (for 48 h) and in combina-
tion with or without the agonistic apoptosis-inducing antibody IgG3 anti–APO-1, 100 ng/ml, for an additional 24 h. The rate of cell death was as-
sessed by cytotoxicity assay (MTT). Data are expressed as 100 2 fraction of the living cells treated with the specific anticancer drug only. A balanced
two-way ANOVA revealed a synergistic interaction between anti–APO-1– and chemotherapy-induced cell death for all the drugs tested (P ,
0.0001, tested in HepG2).
¶Range of data from tests in HepG2, Hs746T, AGS, and MCF7.
**Range of data from tests in HepG2, Hs746T, and MCF7.
‡‡Range of data from tests in HepG2.
§§Could not exactly be quantified by FACScanÒ due to autofluorescence of doxorubicin.
iiRange of data from tests in HepG2, Hs746T, and AGS.
¶¶These data have been published in part (for HepG2) in reference 6.2037 Müller et al.
phosphamide, and bleomycin led to upregulation of CD95
mRNA (6) and of the CD95 receptor protein in HepG2
cells (wt p53), in AGS cells (wt p53), in HS746T cells (wt
p53), and in MCF-7 cells (wt p53) (Table 1, and Figs. 1
and 2). In contrast, no induction or only weak induction of
the CD95 receptor was observed in Huh7 and HT29 cells
with mt p53, and in Hep3B cells lacking p53 altogether.
All drugs tested induced the CD95 receptor in cells with
wt p53 independent of their mechanism of action (Table
1). A wide range of drug concentrations were tested, and it
is of note that clinically relevant concentrations were effec-
tive in upregulation of the CD95 receptor with all drugs
tested.
Increased Responsiveness towards Induction of Apoptosis by 
Anti–APO-1 Antibodies
Upregulation of CD95 receptor expression after cyto-
static treatment resulted in increased responsiveness to-
wards CD95-mediated apoptosis. Hepatoma cells with dif-
ferent p53 mutational status were treated with diverse
anticancer drugs alone or in combination with the agonistic
apoptosis-inducing antibody IgG3 anti–APO-1. In HepG2
cells, treatment with anticancer drugs for 48 h followed by
stimulation of the CD95 receptor with anti–APO-1 re-
sulted in induction of apoptosis in up to 70% of the cells,
dependent on the concentration and the particular drug ap-
plied (Fig. 3). Thus, a statistically significant (P , 0.0001)
synergy in induction of apoptosis by anticancer drugs and
by anti–APO-1 was seen for all the drugs tested (Table 1).
Induction of CD95L by Anticancer Drugs
CD95L mRNA was induced upon cytostatic treatment
in HepG2 cells (wt p53) as well as in Hep3B (p532/2) and
Huh7 cells (mt p53). Thus, cytostatic treatment stimulated
CD95L mRNA expression in different hepatoma cell lines
independent of the p53 status of the cells. The ability to in-
duce CD95L mRNA expression occurred regardless of the
Figure 1. FACSÒ analysis of CD95 re-
ceptor expression in AGS (wt p53) and
HT29 cells (mt p53). Clinically relevant
concentrations of diverse anticancer drugs
with different mechanisms of action induce
CD95 receptor expression (dependent on
the p53 status). As an example for the inves-
tigated cell lines expressing either wt or mt
p53, AGS colon cancer cells and HT29 co-
lon cancer cells are shown here. Enhanced
CD95 receptor expression was observed in
hepatoma, gastric, colon, and breast cancer
cell lines with wt p53 only. Percent en-
hanced CD95 expression was calculated as
(% CD951 treated cells – % Quantum Red1
treated cells) – (% CD951 control cells – %
Quantum Red1 control cells). AGS cells,
for example, displayed enhanced CD95 re-
ceptor expression: up to 60% positive cells
in response to mitomycin, up to 20% in re-
sponse to 5-fluorouracil, and up to 50%
positive cells in response to bleomycin.
Figure 2. Quantitative flow cytometry analysis of CD95 receptor
expression in different solid human tumor cell lines after treatment with
diverse anticancer drugs. *Clinically relevant concentrations of the cyto-
static drugs. Percent CD95 expression was calculated as % CD951 cells 2
% Quantum Red1 cells. Only cell lines with wt p53 expression, HepG2,
AGS, HS746T, and MCF-7 (filled symbols), displayed upregulated CD95
receptor expression up to .80% positive cells in response to drug treat-
ment. In contrast, neither Hep3B cells lacking p53 nor Huh7 and HT29
cells (open symbols) with mt p53 responded to cytotoxic treatment with
upregulation of the CD95 receptor.2038 p53 and CD95 in Drug-induced Apoptosis
mechanism of action of the anticancer drug (Fig. 4). How-
ever, it is of note that there was a high variability in the ex-
tent of CD95L induction dependent on the chemothera-
peutic agent used and the cell line tested. Furthermore,
anticancer drugs with clinically known therapeutic effectiv-
ity for the specific tumor were observed to be most effec-
tive in CD95L induction, e.g., mitoxantrone in hepatomas
and hepatoblastomas (Fig. 4) or 5-fluorouracil in cell lines
from colorectal cancer (data not shown). Anticancer drugs
with different mechanisms of action also upregulated CD95L
mRNA expression in the gastric cancer cell line Hs746T
(wt p53) and in the colon cancer cell line HT29 (mt p53),
independent of the p53 status of the tumor cells (data not
shown).
These data are supported by the fact that CD95L
mRNA was highly elevated upon bleomycin treatment of
Hep3B cells stably transfected with the temperature-sensi-
tive mutants p53ala143 or p53val135. CD95L mRNA up-
regulation occurred both at 328C and at 378C, i.e., at both
wt and mt conformations (Fig. 5).
Our data in the above experiments suggest that cytostatic
drugs upregulate both CD95 and CD95L, the former de-
pendent and the latter independent of the p53 status.
Figure 3. Increased responsiveness towards induction of apoptosis by
CD95 receptor stimulation after treatment with anticancer drugs. Cyto-
toxicity assay with MTT staining of viable cells. HepG2 cells (wt p53, in-
verted triangles), Huh7 cells (mt p53, squares), and Hep3B cells (p532/2, di-
amonds) were treated with different doses of 5-fluorouracil, methotrexate,
mitomycin, cisplatin, mitoxantrone, doxorubicin, etoposide, and cyclo-
phosphamide alone for 48 h and in combination with or without IgG3
anti–APO-1, 100 ng/ml, for an additional 24 h. Data are expressed as the
fraction of living cells treated with specific anticancer drug only (mean 6
SD, n 5 6 wells). Only HepG2 cells with wt p53 exhibited an increased
responsiveness towards induction of apoptosis by agonistic anti–APO-1
antibodies after cytostatic treatment. Anti–APO-1 treatment did not in-
duce further toxicity in Huh7 cells (mt p53) or Hep3B cells (p532/2).
*By MANOVA, between-subject effect P , 0.0001 compared with
Hep3B, P , 0.0001 compared with Huh7.
Figure 4. Induction of the CD95L by cytostatic drugs with different
mechanisms of action. Semiquantitative PCR analysis of CD95L mRNA
expression in HepG2, Hep3B, and Huh7 cells upon treatment with cy-
clophosphamide (cyclo), 5-fluorouracil (5-FU), doxorubicin (doxo), mito-
mycin (mitom), mitoxantrone (mitox), and actinomycin (actino). CD95L
mRNA expression was induced in HepG2 (wt p53), Hep3B (p532/2),
and Huh7 cells (mt p53). Densitometry was performed to analyze CD95L
expression in relation to b-actin expression. CD95L mRNA induction
was independent of the p53 status of the cells. The extent of CD95L ex-
pression upon chemotherapeutic treatment showed variability dependent
on the agent and the cell line tested.
Figure 5. Induction of the CD95L by bleomycin (bleo) in the tempera-
ture-sensitive (ts) mutants p53ala143 and p53val135. Semiquantitative
PCR analysis of CD95L mRNA expression in Hep3B cells stably ex-
pressing the temperature-sensitive mutant p53ala143 or p53val135.
Densitometry was performed to quantify CD95L expression in relation to
b-actin expression. Bleomycin treatment induced CD95L mRNA ex-
pression in the temperature-sensitive mutants p53ala143 and p53val135 at
both temperatures, independent of their p53 mutational status.2039 Müller et al.
Restitution of wt p53 Induces the CD95 Receptor
Our data show a strong correlation between wt p53 sta-
tus and induction of CD95 receptor expression in cancer
cells exposed to chemotherapeutic drugs. This relationship
was further characterized using Hep3B cells transfected (a)
transiently with wt p53 cDNA, (b) stably with a tamoxifen-
regulated p53–estrogen receptor chimera, (c) stably with
the temperature-sensitive mutant p53val135, and (d) stably
with the temperature-sensitive mutant p53ala143.
Transient Transfection with wt p53 cDNA. Cells transfected
with wt p53 cDNA responded with upregulation of the
CD95 receptor upon bleomycin treatment. In contrast,
bleomycin treatment did not lead to an upregulation of the
CD95 receptor in mock-transfected Hep3B cells (Fig. 6).
Stable Transfection with a Tamoxifen-regulated p53–estrogen
Receptor Chimera. Hep3B cells stably transfected with a
p53–estrogen receptor chimera (BT-4P) were treated with
100 nM 4-OH tamoxifen for 24 h to activate p53. BT-2E
control cells transfected with the puromycin resistance gene
only were treated with bleomycin for 48 h. Induction of
p53 upon tamoxifen treatment led to upregulation of the
CD95 receptor from 0–8% of the cells. When bleomycin
treatment was also included, the CD95 receptor expressing
cells increased to 30% (Fig. 7 A). In contrast, BT-2E cells
did not exhibit CD95 receptor expression either before or
after tamoxifen treatment (Fig. 7 B). Significantly, upregu-
lation of CD95 receptor expression after reconstitution of
wt p53 activity was of functional consequence. Thus, stim-
ulation of the upregulated CD95 receptor in BT-4P cells
with the agonistic antibody IgG3 anti–APO-1 resulted in
greatly enhanced apoptosis (Fig. 7 C).
Stable Transfection with the Temperature-sensitive p53 Mu-
tants. At 378C p53val135 and p53ala143 are in an mt
conformation and can transform cells through a negative
dominant mechanism, whereas at the permissive tempera-
ture of 328C they become transcriptionally active and re-
gain wt activity. 40% of Hep3B cells, stably transfected
with the temperature-sensitive mutant p53val135, exhib-
ited CD95 receptor expression at 328C (wt p53 conforma-
tion). In contrast, at 378C (mt p53 conformation) no CD95
receptor expression could be detected. Addition of bleo-
mycin led to a further increase in CD95 receptor–express-
ing cells up to 70% (Fig. 8 A). Likewise, Hep3B cells stably
transfected with the temperature-sensitive mutant p53ala143
only showed upregulation of the CD95 receptor at the per-
missive temperature. Upon addition of bleomycin, CD95
receptor–expressing cells increased to 30% (Fig. 8 B).
Taken together, these data support the conclusion that wt
p53 activity is essential for drug-induced CD95-mediated
apoptosis. Furthermore, these data prompted us to investi-
gate the molecular basis for the regulation of CD95 gene
expression by p53.
Analysis of Putative p53-response Elements in the
CD95 Gene
To further investigate whether p53 interacts directly
with the CD95 gene, we first performed a computer search
for potential p53-responsive elements within the promoter
of the CD95 receptor gene. This search indicated the pres-
ence of three putative elements within the CD95 promoter
which showed limited homology with the p53 consensus
binding site (63). However, it is of note that each of these
putative elements diverges from the consensus in at least
one of the positions corresponding to critical DNA–pro-
tein contact residues, questioning their ability to function as
effective p53 response elements (Fig. 9, A and C). There-
fore, a more comprehensive, experimental approach was
undertaken to search for possible p53-binding elements
within the CD95 gene. A recombinant cosmid comprising
the entire human CD95 locus (cAPO-1 [55]) was subjected
to an immunoselection protocol, which specifically en-
riches DNA fragments containing high-affinity p53-bind-
ing sites (56). This selection procedure resulted in efficient
enrichment of a single p53-binding plasmid clone, carrying
a human genomic DNA insert of 0.7 kb (data not shown);
no other clones were enriched, suggesting that the isolated
Figure 6. Restitution of a wt
p53 status restores the ability of
the p532/2 cell line Hep3B to
increase the CD95 receptor
upon anticancer treatment
(FACSÒ analysis). Transient
transfection of p532/2 Hep3B
cells with wt p53. Either a wt
p53 expression plasmid in which
expression of the p53 gene is un-
der the control of the CMV promoter, or the corresponding control plas-
mid without the p53 insert (mock) was transiently transfected into Hep3B
cells. Upon transient transfection with wt p53 cDNA and bleomycin
treatment, p532/2 Hep3B cells increased CD95 receptor expression.
Figure 7. Induction of the
CD95 receptor by tamoxifen ac-
tivation of a p53–estrogen recep-
tor fusion protein in stably trans-
fected p532/2 Hep3B cells
(FACSÒ analysis). The p532/2
cell line Hep3B was stably trans-
fected with either puromycin re-
sistance alone (control cell line:
BT-2E) or with a p53 (modi-
fied)–estrogen receptor chimera
(cell line: BT-4P). In BT-4P
cells, p53 activity is induced by
addition of the specific ligand
4-OH tamoxifen. The tamoxifen-
activated p53 induces CD95 re-
ceptor expression in BT-4P cells.
A further increase in CD95 re-
ceptor expression up to 30% of
the cells is induced by bleomycin
treatment (A). BT-2E did not
exhibit CD95 receptor expres-
sion either before or after tamox-
ifen treatment (B). The func-
tionality of the upregulated CD95 receptor in BT-4P cells is evident
upon treatment of BT-4P with IgG3 anti–APO-1. Stimulation of the
CD95 receptor by IgG3 anti–APO-1 and concurrent bleomycin treat-
ment lead to an increased rate of apoptosis, after tamoxifen activation of
p53 in BT-4P cells (C, 1 tamo 1 anti-APO).2040 p53 and CD95 in Drug-induced Apoptosis
clone may represent the only high-affinity p53-binding el-
ement within the CD95 genomic cosmid.
The sequence of the first 266 nucleotides of the cloned
0.7-kb insert is shown in Fig. 10 A. It is derived from
within the first intron of the human CD95 gene; its 59 end
is located 142 nucleotides downstream of the 39 end of
exon 1 (Fig. 10 B). The cloned DNA fragment contains a
stretch of 20 contiguous nucleotides (underlined) exhibit-
ing a high degree of homology (18/20, including full con-
servation of all critical core nucleotides) with the p53 con-
sensus binding site (63; Fig. 10 C).
The CD95 p53-binding Element Confers Transcriptional 
Activation by p53, and Cooperates with the CD95 Promoter
To test whether the intronic p53-binding fragment of the
CD95 gene can mediate p53-dependent transcriptional acti-
vation, several luciferase-based reporter plasmids were con-
structed and assayed by transient transfection. A schematic
drawing of the relevant plasmids used for this purpose is
presented in Fig. 11. In plasmid CD95(Ps)-luc the luciferase
gene is preceded by the 1.43-kb CD95 promoter and the 59
end of exon 1 (57; HindIII-SacII fragment, see Fig. 10 B).
In plasmid CD95(P)-luc the luciferase gene is preceded by
the 1.9-kb CD95 promoter and the 59 end of exon 1 (58)
comprising the three computer-suggested putative p53-
binding elements (Fig. 9 B). In CD95(I1SV)-luc, the 0.7-
kb CD95 intronic DNA fragment is positioned in front of a
minimal SV40 promoter. CD95(Ps1I)-luc contains the
CD95 promoter upstream of the CD95 intronic region.
Reporter plasmids were transfected transiently into
Hep3B human hepatoma cells (Fig. 11). As seen in Fig. 11,
the CD95 promoter alone (Ps and P) was only minimally
(up to twofold) stimulated by wt p53, irrespective of
whether the 1.43- or 1.9-kb version of the CD95 pro-
moter was used. These data suggest that this promoter con-
tains only weak p53-responsive elements. On the other
hand, when the CD95 promoter was placed in conjunction
Figure 8. Restitution of inducible wt p53 function restores the ability
of p532/2 Hep3B cells to upregulate the CD95 receptor in response to an-
ticancer drugs. FACSÒ analysis of CD95 receptor expression in Hep3B
clones stably expressing the temperature-sensitive (ts) mutant p53val135
(A) or p53ala143 (B). These temperature-sensitive mutants show mt p53
conformation at 378C; at 328C, the permissive temperature, they regain wt
p53 characteristics. The CD95 receptor is inducible only at the permissive
temperature, 328C. In the temperature-sensitive mutant p53val135, tem-
perature down-shift induces the CD95 receptor in up to 40% of the cells;
additional treatment with bleomycin leads to CD95 expression in up to
70% of the cells (A). Likewise, in the temperature-sensitive mutant
p53ala143, CD95 receptor expression increased to 30% of the cells upon
temperature down-shift and additional bleomycin treatment (B).
Figure 9. (A) Map of the human CD95 gene. Exons 1–9 are numbered
and represented by black boxes. (B) Position of the putative p53 binding
elements (p53-BE) within the CD95 gene promoter, suggested by com-
puter analysis. Numbering is according to Wada et al. (reference 57).
Shown also is a comparison between each element and the consensus
p53-binding site (bottom [reference 63]). R, purine; Y, pyrimidine; W, A
or T. *Putative. Lower case letters indicate deviations from the consensus.
Figure 10. The intronic p53-binding site within the CD95 gene. (A)
Sequence of the first 266 nucleotides of the Sau3A1 fragment, which
contains the p53-binding site in the first intron of the CD95 gene (se-
quence data available from EMBL/GenBank/DDBJ under accession no.
AJ011034). Numbering is according to Wada et al. (reference 57).
p53BE, the putative p53-binding element. (B) Position of the putative
p53-binding element within the CD95 gene. Numbering is as in Wada et
al. (reference 57); the first ATG of the CD95 protein coding region is in-
dicated. (C) Comparison between the CD95 intronic putative p53-bind-
ing element (top line) and the consensus p53-binding site (bottom line; ref-
erence 63). R, purine; Y, pyrimidine; W, A or T. Lower case letters
indicate deviations from the consensus.2041 Müller et al.
with the p53-binding intronic CD95 DNA region (Ps1I),
transcriptional activity became strongly stimulated by wt
p53 (Fig. 11) but not by a tumor-derived p53 mutant (data
not shown). It is of note that the basal activity of this
plasmid, in the absence of p53, was very low and almost
similar to that of the CD95 promoter alone; this combina-
tion of control elements resulted in substantial transcrip-
tional activity only in the presence of p53. Of note, when
the intronic p53-binding fragment was placed in front of an
irrelevant SV40 promoter, activation by p53 was signifi-
cantly less dramatic than in the context of the natural
CD95 promoter (I1SV, Fig. 11). These results were sup-
ported by data in a different cellular context, in H1299 hu-
man lung adenocarcinoma cells (see legend to Fig. 11). A
similar ability to confer p53-dependent transcriptional acti-
vation was also provided when a shorter version of the in-
tronic region was placed downstream of the CD95 pro-
moter (Ps1Is; 34-fold activation). In addition, the effect of
p53 was specific for CD95, and was not exerted on the
RSV promoter, which does not contain any p53-respon-
sive elements (0.95-fold activation). Furthermore, the ex-
tent of stimulation by p53 (fold activation) of the CD95
promoter plus intronic region was comparable to that seen
with a natural p53-responsive promoter derived from the
cyclin G gene (36-fold activation).
Taken together, these data imply that the first intron of
the CD95 gene harbors a p53-responsive enhancer ele-
ment. This element cooperates preferentially with its au-
thentic promoter, and less so with an irrelevant viral pro-
moter. Hence, cooperativity exists between this intronic
p53 response element and one or more elements residing
within the promoter region of the CD95 gene.
Discussion
The data in this paper show that the CD95 system plays
a general role in induction of cytotoxicity by anticancer
drugs in a variety of cells of different histotype. Clinically
relevant concentrations of diverse anticancer drugs such as
cisplatin, bleomycin, methotrexate, doxorubicin, cyclo-
phosphamide, etoposide, and mitoxantrone induce CD95
receptor expression in hepatoma, gastric cancer, colon can-
cer, and breast cancer cell lines, thereby strongly increasing
the sensitivity towards CD95-induced apoptosis. Thus,
chemotherapy may sensitize tumor cells by upregulating
expression of death regulators such as the CD95 receptor.
Most notably, drug-induced upregulation of the CD95 re-
ceptor is dependent on the p53 status of the tumor cell.
Upregulation of the CD95 receptor occurred only in cell
lines with intact p53. This upregulation is dependent on
accumulation of endogenous p53 after DNA damage and
can be reconstituted in p53 null cell lines by exogenous wt
p53 transfection. Caspase-8 cleavage was observed in cell
lines of solid human tumors upon treatment with antican-
cer drugs, irrespective of whether or not apoptosis was de-
pendent on the CD95 system (data not shown). Hence, ad-
ditional effector pathways besides CD95/CD95L signaling
are likely to contribute to drug-induced apoptosis. We fur-
ther show for different solid tumors that anticancer drugs at
concentrations measured during chemotherapy in patients’
sera lead to upregulation of both the CD95 receptor and
CD95L. Upregulation of CD95L upon treatment with an-
ticancer drugs was demonstrated in cell lines containing ei-
ther wt p53, mt p53, or no p53 at all. Thus, the regulation
of CD95L clearly involves p53-independent mechanisms.
Upregulation of the CD95 receptor might render a tu-
mor cell chemotherapy sensitive (and sensitive towards
CD95L-expressing antitumor T cells). Upregulated CD95L
might bind to an increased number of CD95 receptors. On
the contrary, drug resistance could result from downregula-
tion of the CD95 receptor. In fact, we have previously
demonstrated loss of CD95 receptor and gain of CD95L
expression in hepatocellular carcinomas in patients (64).
Constitutive CD95L expression has also been shown for
melanoma (65), lung cancer (66), and colon cancer (67). In
addition, cytostatic drug treatment can induce production
of CD95L. However, drug-induced expression of CD95L
in CD95 receptor–negative tumors cannot be effective and,
furthermore, could result in selective elimination of antitu-
mor lymphocytes. Thus, chemotherapy might render the
tumor an immune-privileged site. Invading T cells, nor-
mally engaged in destruction of the tumor tissue, might be
eliminated through CD95L produced by the target cells.
There are several reports demonstrating that CD95L might
be useful for creating immune-privileged tissues in the con-
Figure 11. The p53-binding intronic CD95 region confers p53-depen-
dent transcriptional activation. (Left) Schematic diagram of relevant lu-
ciferase reporter constructs used for transcriptional analysis. Ps, 1.43-kb
CD95 promoter region (reference 57); P, 1.9-kb CD95 promoter region
with the three putative (computer-identified) p53-binding sites (reference
58); I, CD95 0.7-kb intronic region selected for p53 binding; SV, SV40
minimal promoter; Luc, luciferase gene; p53-BE, p53-binding element.
(Right) Analysis of p53-dependent luciferase activity. Hep3B cells were
transfected with 1 mg of each of the indicated reporter plasmids together
with 100 ng of either a wt p53 expression plasmid, pCMVp53wt, or an
equivalent amount of empty vector. Shown is the fold p53-dependent ac-
tivation of each reporter plasmid, calculated relative to the value obtained
with the same reporter in the absence of p53. These results were supported
in H1299 human lung cancer carcinoma cells: the CD95 promoter alone
was only minimally stimulated by wt p53, highly activated (34-fold) in con-
junction with the p53-binding intronic region in the long (Ps1I) or short
(Ps1Is) version downstream of the CD95 promoter. The effect was CD95
promoter specific, not seen with the RSV promoter (devoid of a p53-
responsive element, 0.95-fold activation), and comparable to activation
(36-fold) with a natural p53-responsive promoter of the cyclin G gene.2042 p53 and CD95 in Drug-induced Apoptosis
text of tumor immune privilege and organ and tissue trans-
plantation (68–71). On the other hand, CD95L-expressing
fibroblasts transplanted into nude mice were readily re-
jected as a result of massive neutrophilic infiltration of the
graft (72). This demonstrates that CD95L expression might
not always support survival of the respective tissue.
On the other hand, tumor cells that express the CD95
receptor upon induction by anticancer therapy may be
turned into susceptible targets for killer cells. Clinical out-
come, i.e., death or survival, might be determined by a bal-
ance between CD95 receptor and CD95L expression on
tumor and immune cells. Upregulation of the CD95 recep-
tor may prepare the tumor cells to be eliminated by the im-
mune system using a CD95-dependent pathway. Thus, in
addition to their direct cytotoxic effects, chemotherapeutic
drugs sensitize tumor cells to CD95-mediated cytotoxicity
and CD95-dependent immune clearance.
Most importantly, our data suggest a potential mecha-
nism by which p53-dependent cell death may be mediated.
We show a strong correlation between p53 status and in-
duction of CD95 receptor in response to DNA damage.
Both DNA damage and transfection/restitution of wt p53
caused induction of the CD95 receptor, and DNA damage
failed to induce the CD95 receptor in tumor cells with mt
or deficient p53. The hypothesis that the CD95 gene is p53
regulated was further confirmed in several systems with sta-
bly transfected inducible p53.
To investigate if p53 directly transactivates the CD95
gene in a manner similar to its effects on CDKN1A (23–
26), gadd45 (20, 73), mdm2 (56, 74), cyclin G (59, 75),
and BAX (27), we looked for p53 response elements in the
CD95 gene. Computer analysis suggested three potential
p53 response elements within the CD95 promoter. How-
ever, the CD95 promoter alone was only minimally stimu-
lated by wt p53, and activation of no more than twofold
was obtained. On the other hand, direct cloning of p53-
binding elements from the entire human CD95 locus
yielded a DNA fragment containing a strong p53-binding
site. This site, derived from the first intron of the human
CD95 gene, displays a high degree of homology with the
p53 consensus binding site (63). When the CD95 promoter
was then placed in conjunction with this p53-binding
DNA region, transcriptional activity became strongly stim-
ulated (up to 50-fold) in transfected hepatoma and lung
carcinoma cells. This suggests a cooperativity between
the intronic element and putative p53 response elements
within the CD95 promoter. Further evidence for such
cooperativity is provided by the observation that the in-
tronic CD95 element is far less potent in conferring
p53-responsiveness in conjunction with an irrelevant SV40
promoter.
Interestingly, there is a remarkably high similarity be-
tween the two adjacent 10-mer half-sites of this putative
p53-binding element; only the first and tenth nucleotides
are not identical between the two half sites. This argues for
the possibility that the CD95 intronic p53-binding site may
be recognized by a specific form of p53 with distinct bind-
ing site preferences.
The observation that the CD95 gene can only be acti-
vated by wild-type but not by the p53 mutants tested
would also argue for a differential regulation of the CD95
gene by wt and mt p53. We hypothesize that wt p53 can
stimulate CD95 gene transcription, whereas the mt p53
protein or specific mutants of p53 protein fail to function
properly in transcription of the CD95 gene. A differential
regulation by wt and mt p53 is also known for the IGF-
IR (insulin-like growth factor I receptor) promoter. wt
p53 has the potential to suppress the IGF-IR promoter,
whereas mutant versions of the p53 protein can derepress
the IGF-IR promoter (76). Further studies are needed in
view of the more than 150 different p53 mutations de-
scribed in human cancers so far to characterize the kind of
mutations that lead to loss of the ability of p53 to act as a
transcription factor of the CD95 gene.
The fact that wt p53 has a stimulatory effect on CD95
gene activity, whereas the investigated mt p53 proteins are
not capable of activating the CD95 gene, may explain why
mutations in p53 contribute to tumor progression and re-
sistance of cancer cells to chemotherapy. Clinical studies
will have to show if p53 and CD95 status are correlated in
primary human tumors and if treatment response to cancer
chemotherapeutic drugs and prognosis are dependent on
p53 and the CD95 apoptotic pathway. Preliminary data
from ongoing clinical studies in patients with hepatocellular
carcinoma show that the majority of the tumors with wt
p53 express the CD95 receptor, whereas only a minority of
the hepatocellular carcinomas with mutant p53 display
CD95 expression (our unpublished observations).
Furthermore, the ability of wt p53 to activate CD95
gene expression and confer sensitivity to CD95-mediated
apoptosis in Hep3B cells may have implications for wt p53
gene therapy. Our data suggest that upregulation of the
CD95 receptor contributes to the apoptosis-inducing effect
of wt p53. These findings may provide an explanation for
the tumor regression observed in non-small cell lung can-
cer patients after wt p53 gene transfer (77). Upregulation of
the CD95 receptor in CD95L-positive tumors may account
for the increased rate of apoptosis reported to occur in
these tumors after wt p53 gene transfer. CD95L expression
may have been acquired during the course of tumor devel-
opment as an immune-privileged site or may have been in-
duced in the tumor cells upon cytostatic treatment. Thus,
wt p53 gene transfer and chemotherapy could synergize in
their action on CD95 receptor and CD95L expression and
induce autocrine and paracrine apoptosis. A synergistic
effect of wt p53 gene transfer and chemotherapeutic treat-
ment on induction of apoptosis has already been reported
in vitro for lung cancer cell lines (77–79). Our data provide
evidence that activation of the CD95 system may be the
molecular basis for this enhancement of apoptosis. Thus,
reconstitution of p53 function with or without combined
chemotherapy is an attractive goal for somatic gene therapy
in cancer.
We have shown that p53 directly transactivates the
CD95 gene. A critical question is whether p53-induced
apoptosis is functionally dependent on the induction of the2043 Müller et al.
CD95 gene. With the identification of killer/DR5 (80) as
another pathway of p53-dependent apoptosis after DNA
damage, it is evident that p53-dependent apoptosis is not
mediated solely by the CD95 system. The observation that
p53-dependent cell death after DNA damage is mediated
by TNF-R family members could have significant implica-
tions for manipulating apoptosis and therapy. 
Interference of anticancer drugs with apoptosis pathways
can take place at several levels, including accumulation of
wt p53 protein, triggering of CD95L–CD95 receptor in-
teraction, triggering of other death receptors, stimulation of
signaling cascades, and activation of death effector mole-
cules including caspases, thus influencing the balance of
proapoptotic and antiapoptotic programs. Therefore, drug
sensitivity and resistance will likely be affected by alter-
ations of any of these components of the apoptosis path-
ways.
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